Neurologic symptoms of IFN therapy, such as psychomotor slowing, fatigue, parkinsonism, and dystonia during IFN treatment are thought to involve alterations in basal ganglia circuitry [65,66]. The gene discussed is IFNA1; the disease is Parkinsonism.